Human in Motion Robotics is commercializing its technology.
The Vancouver-based robotics firm announced this week that XoMotion, which it claims is the world’s most advanced exoskeleton, has received regulatory approval from Health Canada en route to being sold in the country.
XoMotion is designed to aid patients with spinal cord injuries, stroke, and other neurological conditions by providing support through self-balancing and hands-free functionality.
The exoskeleton, on the leading edge of humanoid robotics, reduces the physical burden on therapists by lifting, assisting, mobilizing, and training patients, thus enhancing the safety and efficiency of rehabilitation programs, according to Human in Motion Robotics.
“Our exoskeleton not only empowers patients by facilitating natural and functional movement but also supports therapists by reducing the physical demands of their work,” says cofounder and CEO Siamak Arzanpour.
The omnidirectional XoMotion is now the first self-balancing system available for acquisition in Canada, the company says, with plans to bring the exoskeleton to markets in the US, Europe, and Asia.
“Gaining regulatory approval from Health Canada is a crucial step towards our goal of global accessibility, and we are committed to continuing this progress in other key markets,” Arzanpour said.
XoMotion is available for acquisition in rehabilitation and research facilities in Canada and is globally to scientific investigators conducting robotics research.
“With XoMotion, we are setting a new standard in rehabilitation technology,” Arzanpour said.
Human in Motion was founded in 2016 by Arzanpour alongside Edward Park. Last year, the company closed a $10 million Series A financing round led by Korean firm Beno Holdings.
Leave a Reply